More NewsRead More
Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischem
April 21, 2016
Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
May 20, 2016
Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents
April 13, 2016
category Business & Professional Services
National Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome
February 16, 2016
Pluristem Enters Into Licensing Agreement with TES Holdings Co., Ltd., a Venture Company Derived from the University of Tokyo
April 22, 2016
Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
February 10, 2016
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here